前列腺癌全盆腔IMRT急性肠道毒性:多中心队列肠道剂量体积效应量化
该多中心前瞻性研究纳入415例接受全盆腔调强放疗的前列腺癌患者,评估肠道剂量体积与急性患者报告肠道症状的关系。研究发现肠道环路V46Gy≥80cc与腹泻、急迫感及肠道域总体恶化独立相关,限制V46<80cc可能降低多种中度肠道症状风险。
要点
- 肠道环路V46Gy≥80cc与急性腹泻、急迫感及肠道域总体恶化独立相关。
- 基线IBDQ评分较低者从剂量限制中获益更大。
- 预测模型校准良好且经bootstrap验证稳健。
核心结论
- 限制肠道环路V46<80cc可能降低多种中度肠道症状风险。
- 基线IBDQ评分较低的患者从剂量限制中获益更大。
研究设计与样本
- 多中心前瞻性试验(NCT02803086)纳入415例接受全盆腔调强放疗的前列腺癌患者。
- 根治性、辅助性和挽救性治疗意图分别占31%、33%和36%,盆腔淋巴结中位剂量53Gy。
- 采用炎症性肠病问卷肠道域评估基线至放疗中点/结束的毒性变化(ΔIBDQ)。
- 以ΔIBDQ第25百分位值为终点,排除基线评分<5者(各终点排除率2%-7%)。
- 将最佳剂量学预测因子与临床参数通过多因素逻辑回归构建预测模型。
主要发现
- 各IBDQ症状ΔIBDQ范围为0.2-1.5分,仅IBDQ1频率、IBDQ5腹泻、IBDQ17排气、IBDQ24急迫感的中位恶化≥1。
- DVH可预测IBDQ5腹泻、IBDQ24急迫感和肠道域总体的症状恶化风险。
- 多因素分析中DVH(最佳截断值V46Gy≥80cc)和基线评分(OR 0.35-0.65)与三个终点独立相关。
- 模型可靠(H&L检验0.453-0.956)、校准良好(斜率0.922-1.069,R² 0.725-0.875)、区分度中等(AUC 0.628-0.669)。
- 基于bootstrap的验证证实模型稳健。
关键数值与推荐
- 肠道环路V46Gy≥80cc为最佳剂量学截断值。
- 基线评分OR范围为0.35-0.65。
- 模型H&L检验P值0.453-0.956,校准斜率0.922-1.069,R² 0.725-0.875,AUC 0.628-0.669。
临床怎么用
- 全盆腔IMRT计划设计时可将肠道环路V46Gy<80cc作为剂量约束目标。
- 对基线肠道症状评分较低的患者应优先关注剂量限制以降低症状恶化风险。
- 可参考所建预测模型评估个体患者急性肠道症状风险。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. MATERIALS AND METHODS: Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53 Gy were available. The most severe changes between baseline and radiotherapy mid-point/end toxicity assessed by Inflammatory Bowel Disease Questionnaire (only Bowel Domain) were considered (ΔIBDQ). The 25th percentile values of these score variations were set as endpoints. DVHs of bowel loops for patients with/without toxicity were compared for each endpoint, having excluded patients with baseline scores <5 (rate ranging between 2% and 7% according to the endpoint): the resulting best dosimetric predictors were combined with selected clinical parameters through multivariate logistic regression (MVA) to derive predictive models. RESULTS: ΔIBDQ ranged between 0.2-1.5 points considering separately each IBDQ symptom. Only four symptoms (IBDQ1 = frequency, IBDQ5 = diarrhea, IBDQ17 = gas passage, IBDQ24 = urgency) showed a median worsening ≥ 1; DVH predicted the risk of worse symptoms for IBDQ5, IBDQ24 and overall Bowel Domain. At multivariable analysis DVHs (best cut-off: V46Gy ≥80 cc) and baseline scores (Odd-Ratio:0.35-0.65) were independently associated to the three end-points. The resulting models were reliable (H&L test: 0.453-0.956), well calibrated (calibration plot: slope = 0.922-1.069, R2 = 0.725-0.875) and moderately discriminative (Area Under the Curve:0.628-0.669). A bootstrap-based validation confirmed their robustness. CONCLUSION: Constraining the bowel loops (V46 < 80 cc) may reduce the risk of several moderate intestinal symptoms, with a much greater impact for patients with lower IBDQ baseline scores.
引用
- Bresolin A, Faiella A, Garibaldi E, et al. Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiother Oncol. 2021. PMID: 33639190. doi:10.1016/j.radonc.2021.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。